SCD1 Inhibitor, SCD1(stearoyl-CoA desaturase 1) inhibitor (ab142089)
Key features and details
- Potent, selective SCD1(stearoyl-CoA desaturase 1) inhibitor
- CAS Number: 1032229-33-6
- Purity: > 99%
- Soluble in ethanol to 10 mM and in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
SCD1 Inhibitor, SCD1(stearoyl-CoA desaturase 1) inhibitor -
Description
Potent, selective SCD1(stearoyl-CoA desaturase 1) inhibitor -
Biological description
Potent, selective SCD1 (stearoyl-CoA desaturase 1) inhibitor (IC50 = 4.5 nM). Inhibits the conversion of saturated, long-chain fatty acyl-CoAs to monounsaturated, long-chain fatty acyl-CoAs in vitro, when heptadecanoic acid and palmitic acid are used as the substrate (IC50 = 7.9 and 6.8 nM, respectively). Active in vivo. Orally bioavailable.
-
Purity
> 99% -
CAS Number
1032229-33-6 -
Chemical structure
Properties
-
Chemical name
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-piperidinecarboxamide -
Molecular weight
387.87 -
Molecular formula
C20H22ClN3O3 -
PubChem identifier
24905400 -
Storage instructions
Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in ethanol to 10 mM and in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CNC(=O)C1=CC(=CC=C1)NC(=O)N2CCC(CC2)OC3=CC=CC=C3Cl -
Source
Synthetic
-
Research areas
Images
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (8)
ab142089 has been referenced in 8 publications.
- Hamilton LK et al. Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimer's disease mouse model. Nat Commun 13:2061 (2022). PubMed: 35443751
- Luis G et al. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 43:102006 (2021). PubMed: 34030117
- Uematsu M & Shimizu T Raman microscopy-based quantification of the physical properties of intracellular lipids. Commun Biol 4:1176 (2021). PubMed: 34625633
- Zhang Q et al. Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res 38:116 (2019). PubMed: 30845964
- Fanning S et al. Lipidomic Analysis of a-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell 73:1001-1014.e8 (2019). PubMed: 30527540
- Piccolis M et al. Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. Mol Cell 74:32-44.e8 (2019). PubMed: 30846318
- Sinha RA et al. Loss of ULK1 increases RPS6KB1-NCOR1 repression of NR1H/LXR-mediated Scd1 transcription and augments lipotoxicity in hepatic cells. Autophagy 13:169-186 (2017). WB ; Mouse . PubMed: 27846372
- Southam AD et al. Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Res 75:2530-40 (2015). PubMed: 25943877